Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
- 172 Downloads
Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC). Nonetheless, it is expensive, effective in few patients, and may cause significant adverse effects. Therefore, accurate selection of patients is needed. In a previous study, we constructed a simple scoring system to predict patients’ outcomes based on the occurrence of sorafenib adverse effects.
The present study aimed to validate this scoring system in a real-life cohort of HCC patients.
Patients and Methods
Clinical records of 279 outpatients treated with sorafenib in eight Italian centers were retrospectively analyzed. Adverse effects considered to calculate the score were skin toxicity, diarrhea, and arterial hypertension, occurring during the first month of therapy. For each adverse effect, 1 point was assigned if present; and 0 points if absent (resulting in a total score between 0 and 3).
Median overall survival (OS) was 10.8 months and median time to progression (TTP) was 5.1 months. At multivariate analysis, performance status, α-fetoprotein (AFP), and Child-Pugh score were independently associated with TTP and OS. A progressive increase of OS and TTP was observed in patients with scores from 0 to 3 (p < 0.001). Six-, 12-, and 24-month survival probabilities were 55.1, 24.5, and 7.9% in score 0 patients, and 100, 80.9, and 46.2% in score 3 patients, respectively. Complete response was observed in one patient (0.4%), partial responses in 41 (15.2%), and stable disease in 117 (43.5%). The disease control rate in patients with scores of 0, 1, 2, and 3 was 34.3, 51.6, 80.9, and 96.3%, respectively (p < 0.001). Complete or partial responses were not observed in score 0 patients.
G.G.D. and R.T. designed the study’s concept. R.T, A.C.G., G.M., F.G.F., L.P., S.C., N.S., V.O.P, G.E., and O.B. contributed to the data collection and analysis. G.G.D. drafted the manuscript. G.G.D. and R.G. revised the manuscript.
Compliance with Ethical Standards
No funding was received for the preparation of this article.
Conflicts of Interest
The authors declare no conflicts of interest.
- 1.Ferlay J, Soerjomataram II, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.Google Scholar
- 4.Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: Translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140–51.Google Scholar
- 5.European Association for the Study of the Liver. EASL–EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.Google Scholar
- 6.Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An update. Hepatology. 2011;53:1020–2.Google Scholar
- 7.Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the liver consensus. Hepatol Int. 2010;4:439–74.Google Scholar
- 10.Cao G, Li X, Qin C, Li J. Prognostic value of VEGF in hepatocellular carcinoma patients treated with Sorafenib: A meta-analysis. Med Sci Monit. 2015;21:3144–51.Google Scholar
- 11.Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol. 2012;57:821–9.Google Scholar
- 12.Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.Google Scholar
- 13.Lencioni R, Kudo M, Ye SL, et al. GIDEON (global investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): Second interim analysis. Int J Clin Pract. 2014;68:609–17.Google Scholar
- 14.Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial. Eur J Cancer. 2012;48:1452–65.Google Scholar
- 15.Song T, Zhang W, Wu Q, et al. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: Evaluation of prognostic factors. Eur J Gastroenterol Hepatol. 2011;23:1233–8.Google Scholar
- 20.Zhang Z, Zhou X, Shen H, et al. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study. BMC Med. 2009;7:41.Google Scholar
- 25.Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: A systematic review. Hepatobiliary Pancreat Dis Int. 2012;11:458–66.Google Scholar
- 28.Shao YY, Shau WY, Chan SY, Lu LC, Hsu CH, Cheng AL. Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials. Oncology. 2015;88:345–52.Google Scholar
- 30.Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Japanese Red Cross Liver Study Group, et al. Proposal of Japan red cross score for sorafenib therapy in hepatocellular carcinoma. Hepatol Res. 2015;45(10):E130–40.Google Scholar
- 31.Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol. 2008;47:176–86.Google Scholar
- 37.Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, et al. Incidence and risk of sorafenib-induced hypertension: A systematic review and meta-analysis. J Clin Hypertens. 2014;16:177–85.Google Scholar
- 38.Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: An updated systematic review and meta-analysis. J Hum Hypertens. 2013;27:601–11.Google Scholar
- 40.Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: Hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013;36:319–24.Google Scholar
- 43.Sica DA. Angiogenesis inhibitors and hypertension: An emerging issue. J Clin Oncol. 2006;24:1329–31.Google Scholar
- 49.Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, et al. Sorafenib in the treatment of hepatocellular carcinoma: A multi-centre real-world study. Scand J Gastroenterol. 2016;51:979–85.Google Scholar